Skip to main content
SpringerLink
Log in

Chemo-Immuntherapie und Vakzinebehandlung des metastasierten Nierenzellkarzinoms

  • Chapter
Pharmakotherapie in der Urologie

  • 66 Accesses

Zusammenfassung

Je weniger gut eine onkologische Therapie für eine Indikation erwiesen ist, desto vielfältiger werden selbst in der seriösen klinischen Praxis die individuellen Überzeugungen und therapeutischen Ansätze definiert. Dies gilt besonders bei den Behandlungsversuchen an Patienten mit metastasiertem Nierenzellkarzinom.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

Literatur

  1. Allen, MJ, Vaughan M, Webb A et al. (2000) Protracted venous infusion 5-fluorouracil in combination with subcutaneous interleukin-2 and alpha interferon in patients with metastatic renal cell cancer: a phase II study. Br J Cancer 83(8): 980–985

    Article  PubMed  CAS  Google Scholar 

  2. Amato R, Wood LS, Savary C, Wood C, Howkins EA, Reitsma DG, Srivastava P (2999) Patients with renal cell carcinoma (RCC) using autologous tumor-derived heat shock protein-peptide complex (HSPPC-96) with or without interleukin-2 (IL-2). Proc ASCO 2000: abstr. 1782

    Google Scholar 

  3. Antonia SJ, Seigne JD (2000) B7–1 gene-modified autologous tumor-cell vaccines for renalcell carcinoma. World J Urol 18: 157–163

    Article  PubMed  CAS  Google Scholar 

  4. Atzpodien J, Kirchner HF, Franzke A et al. (1997) Results of a randomized clinical trial comparing sc interleukin-2, sc alpha-2a-interferon, and iv bolus 5-fluorouracil against oral tamoxifen in progressive metastatic renal cell carcinoma patients. Proc ASCO, abstr. 1164

    Google Scholar 

  5. Atzpodien J, Kirchner H, Bergmann L, Oberneder R, Jonas U, Ganser A (1999) 13cis-retinoic acid, IFN-alpha, IL-2 and chemotherapy in advanced renal cell carcinoma: results of a prospectively randomized trial of the German cooperative renal carcinoma immunotherapy group (DGCIN). Proc ASCO 1999: abstr. 1727

    Google Scholar 

  6. Bain C, Merrouche Y, Puisieux I, Duc A, Colombo MP, Favrot M (1996) B7.1 gene transduction of human renal-cell-carcinoma cell lines restores the proliferative response and cytotoxic function of allogeneic T cells. Int J Cancer 67(6): 769–776

    Article  PubMed  CAS  Google Scholar 

  7. Balkwill FR, Mowshowith S, Seilman SS, Moodie EM, Griffin DB, Fantes KH, Wolf CR (1984) Positive interactions between interferon and chemotherapy due to direct tumor action rather than effect on host drug-metabolizing enzymes. Cancer Res 44: 5249–5255

    PubMed  CAS  Google Scholar 

  8. Bhatti L, Sidell N (1994) Transcriptional regulation by retinoic acid of interleukin-2 alpha receptors in human B cells. Immunology 81: 273–279

    PubMed  CAS  Google Scholar 

  9. Bocchia M, Bronte V, Colombo MP et al. (2000) Antitumor vaccination: where we stand. Haematologica 85: 1172–1206

    PubMed  CAS  Google Scholar 

  10. Braybrooke JP, O’Byrne KJ, Propper DJ et al. (2000) A phase II study of Razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate Markers of angiogenesis. Clin Cancer Res 6: 4697–4704

    PubMed  CAS  Google Scholar 

  11. Brodowicz T, Wiltschke C, Rudas M et al. (1998) Interferon-alpha and retinoids induce proliferation inhibition and apoptosis in soft tissue sarcoma cell in dependence on p53 status. Proc ASCO 1998: abstr. 1965

    Google Scholar 

  12. Brouty-Boye D, Tovey MG (1989) Inhibiton by interferon of thymidine uptake in chemostat cultures of L1210 cells. Intervirology 9: 243–252

    Article  Google Scholar 

  13. Buer J, Probst M, Duensing S et al. (1997) Clinical and in vitro response to 13-cis-retinoic acid in interferon-alpha resistant renal cell carcinoma. Cancer Biother Radiopharm 12: 143–147

    Article  PubMed  CAS  Google Scholar 

  14. Bukowski R, Ernstoff M, Gore M, Amato R, Rose E, Rybak ME, Gupta S (1999) Phase I study of polyethylene glycol (PEG) interferon alpha-2b (PEG INTRON) in patients with solid tumors. Proc ASCO 1999: abstr. 1719

    Google Scholar 

  15. Cao S, Troutt AC, Rustum YM (1998) Interleukin 15 protects against toxicity and potentiates antitumor activity of 5-fluorouracil alone and in combination with leucovorin in rats bearing colorectal cancer. Cancer Res 58: 1695–1699

    PubMed  CAS  Google Scholar 

  16. Childs R, Chernoff A, Contentin N et al. (2000) Regression of metastatic renal cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 343: 750–758

    Article  PubMed  CAS  Google Scholar 

  17. Coppin C, Porzsolt F, Kumpf J, Coldman A, Wilt T (2001) Immunotherapy for advanced renal cell cancer (Cochrane Review). In: The Cochrane Library, 1 (Oxford: Update Software)

    Google Scholar 

  18. Creagan ET, Twito DI, Johansson SL et al. (1991) A randomized prospective assessment of recombinant leukocyte A human interferon with or without aspirin in advanced renal adenocarcinoma. J Clin Oncol 9: 2104–2109

    PubMed  CAS  Google Scholar 

  19. Danhauser LL, Freimann JH, Gilchrist TL et al. (1993) Phase I and plasma pharmacokinetic study of infusional fluorouracil combined with recombinant interferon alfa-2b in patients with advanced cancer. J Clin Oncol 11: 751–761

    PubMed  CAS  Google Scholar 

  20. de Gast GC, Klümpen H-J, Vyth-Dreese FA et al. (2000) Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating Factor, low-dose interluekin 2 and interferon alpha in progressive metastatic melanoma and renal cell carcinoma. Clin Cancer Res 6: 1267–1272

    PubMed  Google Scholar 

  21. De Mulder PHM, Weißbach L, Jakse G, Osieka R, Blatter J (1996) Gemcitabine a phase II study in patients with advanced renal cancer. Cancer Chemother Pharmacol 37: 491–495

    Article  PubMed  Google Scholar 

  22. Dejosez M, Ramp U, Mahotka C, Krieg A, Walczak H, Gabbert HE, Gerharz CD (2000) Sensitivity to TRAIL/APO-2L-mediated apoptosis in human renal cell carcinomas and its enhancement by topotecan. Cell Death Diff 7(11): 1127–1136

    Article  CAS  Google Scholar 

  23. Ehrke JM, Mihich E, Berd D, Mastrangelo MJ (1989) Efffects of anticancer drugs ont the immune system in humans. Sem Oncol 16: 230–253

    CAS  Google Scholar 

  24. Ehrke MJ, Maccubbin D, Ryoyama K, Cohen SA, Michich E (1986) Correlation between adriamycin induced augmentation of interleukin 2 production and of cell-mediated cytotoxicity in mice. Cancer Res 46: 54–60

    PubMed  CAS  Google Scholar 

  25. Einat M, Resnitzky D, Kimche A (1985) Close link between reduction of c-myc expression by interferon and GO/G 1 arrest. Nature 313: 597–600

    Article  PubMed  CAS  Google Scholar 

  26. Elhilali MM, Bleave M, Fradet et al. (2000) Placebo-associated remissions in a multicentre, randomized, double-blind trial of interferon ?lb for the treatment of metastatic renal cell carcinoma. BJU Int 86: 613–618

    Article  PubMed  CAS  Google Scholar 

  27. Elias L, Sandoval JM (1989) Interferon effects upon fluorouracil metabolism by HL-60 cells. Biochem Biophys Res Commun 163: 867–874

    Article  PubMed  CAS  Google Scholar 

  28. Elias L, Binder M, Mangalik Q, Clark D, Morrison B, Altobelli KK, Smith A (1999) Pilot trial of infusional 5-Fluorouracil, interleukin-2 and subcutaneous interferon-alpha for advanced renal cell carcinoma. Am J Clin Oncol 22: 156–161

    Article  PubMed  CAS  Google Scholar 

  29. Escudier B, Chevreau C, Lasset C et al. (1999) Cytokines in metastatic renal cell carcinoma: is it useful to switch to interleukin-2 or interferon after failure of a first treatment? J Clin Oncol 17(7):2039–2043

    PubMed  CAS  Google Scholar 

  30. Fegan C, Bailey-Wood R, Coleman S, Philips SA, Neale L, Hoy T, Whittaker JA (1995) All trans retinoic acid enhances human LAK activity. Eur J Haematol 54: 95–100

    Article  PubMed  CAS  Google Scholar 

  31. Figg WD, Kruger EA (2000) TNP-470: an angiogenesis inhibitor in clinical development for cancer. Expert Opin Investig Drugs 9(6): 1383–1396

    Article  PubMed  Google Scholar 

  32. Figlin RA, Pierce WC, Kaboo R et al. (1997) Treatment of metastatic renal cell carcinoma with nephrectomy, interleukin-2 and cytokine-primed or CD8(+) selected tumor infiltrating lymphocytes from primary tumor. J Urol 158, 3: 740–45

    Article  PubMed  CAS  Google Scholar 

  33. Fischer CG, Waechter W, Kraus S, Perez EF, Weidner W, Dudeck J (1998) Urologic tumors in the Federal Republic of Germany — data report including 56,013 cases from hospital cancer registries. Cancer 82: 775–783

    Article  PubMed  CAS  Google Scholar 

  34. Fisher RI, Rosenberg SA, Fyfe G (2000) Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Aci Am 6 (Suppl. 1): 55–57

    Google Scholar 

  35. Fossa SD, Marinelli G, Otto U et al. (1992) Recombinant interferon alfa-2a with or without vinblastine in metastatic renal cell carcinoma: results of a European multi-center phase III study. Ann Oncol 3: 301–305

    PubMed  CAS  Google Scholar 

  36. Frohn C, Doehn C, Durek C, Böhle A, Schlenke P, Jocham D, Kirchner H (2000) Feasibility of the adoptive transfusion of allogenic human leukocyte antigen-matched natural killer cells in patients with renal cell carcinoma. J Immunother 23(4): 499–504

    Article  PubMed  CAS  Google Scholar 

  37. Fuxius S, Mross K, Mansouri K, Unger C (1999) Phase-I Study with Gemcitabine and interferon alfa-2b in patients with advanced ovarian, pancreatic, kidney and NSCL cancer. Proc. ASCO 1999: abstr. A809

    Google Scholar 

  38. Garattini E, Mologni L, Ponzanelli I, Terao M (1998) Cross talk between retinoic acid and interferons: molecular mechanisms of interaction in acute promyelocytic leukemia cells. Leuk Lymphoma 30: 467–475

    PubMed  CAS  Google Scholar 

  39. Gardner RV (1998) Interferon-gamma (IFN-gamma) as a potential radio- and chemo-protectant. Am J Hematol 58: 218–223

    Article  PubMed  CAS  Google Scholar 

  40. Gelmon KA, Latreille J, Tocher A et al. (2000) Phase I dose-finding study of a new taxane, RPR 109881 A, administered as a one-hour intravenous infusion days 1 and 8 to patients with advanced solid tumors. J Clin Oncol 18: 4098–4108

    PubMed  CAS  Google Scholar 

  41. Gohji K, Maeda S, Sugiyama T, Shigami J, Kamidono S (1987) Enhanced inhibition of anticancer drugs by human recombinant gamma-interferon for human renal cell carcinoma in vitro. J Urol 137: 539–543

    PubMed  CAS  Google Scholar 

  42. Golimbu M, Joshi P, Sperber A, Tessler A, Al-Askari S, Morales P (1986) Renal cell carcinoma: survival and prognostic factors. Urology 27: 291–301

    Article  PubMed  CAS  Google Scholar 

  43. Gollob JA, Mier JW, Veenstra K, McDermott DF, Clancy D, Clancy M, Atkins MB (2000) Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-? induction is associated with clinical response. Clin Cancer Res 6: 1678–1692

    PubMed  CAS  Google Scholar 

  44. Grem JL, Mc Atee NM, Murphy RF (1991) A pilot study of interferon alpha2a in combination with fluorouracil plus high-dos leucovorin in metastatic gastrointestinal carcinoma. J Clin Oncol 9: 1811–1820

    PubMed  CAS  Google Scholar 

  45. Guttermann JU (1994) Cytokine therapeutics: Lessons from interferon a. Proc Natl Acad Sci USA 91: 1198–1205

    Article  Google Scholar 

  46. Hancock B, Griffiths G, Ritchie A et al. (2000) Updated results of the MRC randomised controlled trial of alpha interferon vs. MPA in patients with metastatic renal carcinoma. Proc ASCO 2000: abstr. 1336

    Google Scholar 

  47. Hänninen LE, Kirchner H, Atzpodien J (1996) Interleukin-2-based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients. J Urol 155: 19–25

    Google Scholar 

  48. Henriksson R, Nilsson S, Collen S, Wersall P, Helsing M, Zimmerman R, Engman K (1998) Survival in renal cell carcinoma — a randomized evaluation of tamoxifen vs. Interleukin-2, alpha-interferon (leukocyte) and tamoxifen. Br J Cancer 77,8: 1311–1317

    Google Scholar 

  49. Hofmockel G, Langer W, Theiss M, Gruss A, Frohmüller HG (1996) Immunochemotherapy for metastatic renal cell carcinoma using a regimen of interleukin-2, interferon-alpha and 5-flurouracil. J Urol 156: 18–21

    Article  PubMed  CAS  Google Scholar 

  50. Hofmockel G (1993) Treatment with tumor necrosis factor-alpha and interferon-alpha of a human kidney cancer xenograft in nude mice: evidence for an anticachectic effect of interferon. Urol Res 21: 466 (P98)

    Google Scholar 

  51. Homma A, Aso Y (1994) Effect of alpha-interferon alone and combined with other antineoplastic agents on renal cell carcinoma determined by the tetrazolium microculture assay. Eur Urol 25: 164–170

    PubMed  CAS  Google Scholar 

  52. Hotton KH, Khorsand M, Hank JA et al. (2000) A phase Ib/II trial of granulocyte-macrophage-colony stimulating factor and interleukin-2 for renal cell carcinoma patients with pulmonary metastases. Cancer 88(8): 1892–1901

    Article  PubMed  CAS  Google Scholar 

  53. Huland E, Heinzer H, Huland H, Yung R (2000) Overview of interleukin-2 inhalation therapy. Cancer J Sci Am 6 (Suppl. 1): 104–112

    Google Scholar 

  54. Huland E, Timm S, Heinzer H, Aalamian M, Huland H (2001) Immuntherapie des metastasierten Nierenzellkarzinoms in Deutschland. Vortrag gehalten auf dem 10. Urologischen Winter-Workshop, Maria Alm, 29.1.2001

    Google Scholar 

  55. Igarashi T, Marumo K, Onishi T et al. (1999) Interferon-alpha and 5-fluorouracil therapy in patients with metatatic renal cell cancer: an open multicenter trial. The Japanese Study Group against renal cancer. Urology 53: 53–59

    Article  PubMed  CAS  Google Scholar 

  56. Inoue M, Tan YH (1983) Enhancement of actinomycin D- and cis-diamminedichloroplatinum(II)-induced killing of human fibroblasts by human beta-interferon. Cancer Res 43: 5484–5488

    PubMed  CAS  Google Scholar 

  57. Ishikawa T, Utoh M, Sawada N, Nishida M, Fukase Y, Sekiguchi F, Ishitsuka H (1998) Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts. Biochem Pharmacol 55: 1091–1097

    Article  PubMed  CAS  Google Scholar 

  58. Jezersek B, Novakovic S, Sersa G, Auersperg M, Fleischmann WR (1994) Interactions of interferons and vinblastine on experimental tumor model melanoma B-16 in-vitro. Anti-cancer Drugs 5: 53–56

    Article  PubMed  CAS  Google Scholar 

  59. Kataoka T, Oh-hashi F, Sakurai Y (1984) Encancement of anti-proliferation activity of vincristine and adriamycin by interferon. Jpn J Cancer Res (gann) 75: 548

    CAS  Google Scholar 

  60. Kath R, Schlichter A, Höffken K (1997) Nierenkarzinom. In: Schmoll H-J, Höffken K, Possinger K (Hrsg) Kompendium Internistische Onkologie. 2. Aufl, Springer, Berlin Heidelberg New York Tokyo, S 1299–1331

    Chapter  Google Scholar 

  61. Kawagoe N, Shintaku I, Yutani S, Etoh H, Matuoka K, Noda S, Itoh K (2000) Expression of the SART3 tumor rejection antigen in renal cell carcinoma. J Urol 164: 2090–2095

    Article  PubMed  CAS  Google Scholar 

  62. Kawakami K, Joshi BH, Puri RK (2000) Sensitization of cancer cells to interleukin 13-pseudomonas exotoxin-induced cell death by gene transfer of interleukin 13 receptor alpha chain. Hum Gene Ther 11(13): 1829–1835

    Article  PubMed  CAS  Google Scholar 

  63. Khanna C, Anderson PM, Katsanis E, Noville M, Klausner JS (1997) Interleukin-2 liposome inhalation therapy is safe and effective for dogs with spontaneous pulmonary metastases. Cancer 79: 1409–1421

    Article  PubMed  CAS  Google Scholar 

  64. Kuebler JP, Godette GA, Bock DJ, Epstein, RB (1990) Synergistic effects of vinblastine and recombinant interferon-beta on renal tumor cell lines. J Interferon Res 10: 281–291

    Article  PubMed  CAS  Google Scholar 

  65. Kugler A, Stuhler G, Walden P et al. (2000) Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hydrids. Nature Medicine 6(3): 332–336

    Article  PubMed  CAS  Google Scholar 

  66. Law TM, Motzer RJ, Mazumdar M et al. (1995) Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma. Cancer 76(5): 824–832

    Article  PubMed  CAS  Google Scholar 

  67. Lippman SM, Glission BS, Kavanagh JJ et al. (1993) Retinoic acid and interferon combinations studies in human cancer. Eur J Cancer 29 (Suppl. 5): 9–13

    Article  Google Scholar 

  68. Lümmen G, Brinkmann OA, Luboldt HJ, Hertle L, Rübben H (2001) Interferon-a, interleukin-2 and 5-fluorouracil versus mistletoe lectin metastatic renal cell carcinoma- long-term results. Eur Urol 39 (suppl. 5): 121 (abstr. 475)

    Google Scholar 

  69. Majewski S, Szmurlo A, Marczak M, Jablonska S, Bollag W (1994) Synergistic effect of retinoids and interferon-alpha on tumor-induced angiogenesis: antiangiogenic effect on HPV harboring tumor cell lines. Int J Cancer 57: 81–85

    Article  PubMed  CAS  Google Scholar 

  70. Matheson, DS, Green BJ, Friedman SJ, Hoar DI (1988) Studies on the mechanism of activation of human natural killer function by interferon and inhibitions of thymidylate syntheses. Cell Immunol 111: 118–125

    Article  PubMed  CAS  Google Scholar 

  71. Mertens WC, Eisenhauer EA, Moore M, Venner P, Stewart D, Muldal A, Wong D (1993) Gemcitabin in advanced renal cell carcinoma. A phase II study of the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol 4: 331–332

    PubMed  CAS  Google Scholar 

  72. Mickisch GH, Garin A, Madej M, de Prijck L, Sylvester R (2000) Tumor nephrectomy plus interferon a is superior to interferon a alone in metastatic renal cell carcinoma. J Urol 163 (Suppl 4): 176 (abstr. 778)

    Google Scholar 

  73. Miller WH, Reyno LM, Loewen GR et al. (2000) A phase I/II study of 9-cis retinoid acid and interferon-a2b in patients with advanced renal-cell carcinoma: an NCIC Clinical Trials Group Study. Ann Oncol 11: 1387–1389

    Article  PubMed  Google Scholar 

  74. Motzer RJ, Murphy BA, Bacik J et al. (2000) Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. J Clin Oncol 18: 2972–2980

    PubMed  CAS  Google Scholar 

  75. Motzer RJ, Rakhit A, Ginsberg M et al. (2001) Phase I trial of 40-kd branched interferon alfa-2a for patients with advanced renal cell carcinoma. J Clin Oncol 19(5): 1312–1319

    PubMed  CAS  Google Scholar 

  76. Nanus DM, Guo X, Vargas M, Papanicolaou N, Bander NH, Giudas LJJ (2000) Interferon alfa (IFN plus liposomal-encapsulated all-trans retinoic acid (Lipoantra) for advanced renal cancer (RC). Proc ASCO 2000: abstr. 14736

    Google Scholar 

  77. Négrier S, Escudier B, Lasset C et al. (1996) The FNCLCC CRECY Trial: Interleukin-2 (IL2) + Interferon (IFN) is the optimal treatment to induce responses in metastatic renal cell carcinoma (MRCC). Proc ASCO 1996: 248 (abstr. 629)

    Google Scholar 

  78. Négrier S, Escudier B, Lasset C et al. (1998) Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. New Engl J Med 338: 1272–1278

    Article  PubMed  Google Scholar 

  79. Négrier S, Caty A, Lesimple T et al. (2000) Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with of without fluorouracil. J Clin Oncol 18: 4009–4015

    PubMed  Google Scholar 

  80. Oevermann K, Buer J, Hoffmann R et al. (2000) Capecitabine in the treatment of metastatic renal cell carcinoma. Br J Cancer 83(5): 583–587

    Article  PubMed  CAS  Google Scholar 

  81. Ohmura K, Tsukamoto T (1989) Antiproliferative effect of interferon-alpha on human renal cell carcinoma in clonogenic assay — single and combination effect with cancer chemotherapeutic agent. Hinyokika Kiyo 35: 737–747

    PubMed  CAS  Google Scholar 

  82. Ohno R, Yamaguchi Y, Toge T et al. (2000) A dose-escalation and pharmacokinetic stuy of subcutaneously administered recombinant human interleukin 12 and its biological effects in japanese patients with advanced malignancies. Clin Cancer Res 6: 2661–2669

    PubMed  CAS  Google Scholar 

  83. Oku T, Imanishi J, Kishida T (1982) Assessment of anti-tumor cell effect of human leukocyte interferon in combination with anticancer agents by a convenient assay system in monolayer cell culture. Gann 73: 667–674

    PubMed  CAS  Google Scholar 

  84. Olencki TE, Pratt S, Budd GT, Peereboom DM, McClain D, Bukowski RM (1999) Phase I Trial of capecitabine and subcutaneous interferon-alpha in renal cell carcinoma (RCC). Proc. ASCO 1999: abstr. 855

    Google Scholar 

  85. Pagliaro L, Daliani D, Amato R et al. (2000) A phase II trial of Bryostatin-1 for patients with metastatic renal cell carcinoma. Cancer 89(3): 615–618

    Article  PubMed  CAS  Google Scholar 

  86. Plonowski A, Schally AV, Nagy A, Kiaris H, Hebert F, Halmos G (2000) Inhibition of metastatic renal cell carcinomas expressing somatostatin receptors by a targeted cytotoxic analogue of somatostatin AN-238. Cancer Res 60: 2996–3001

    PubMed  CAS  Google Scholar 

  87. Pohla H, Frankenberger B, Stadlbauer B et al. (2000) Allogeneic vaccination for renal cell carcinoma: development and monitoring. Bone Marrow Transplant 26 (Suppl. 2): 83–87

    Article  Google Scholar 

  88. Portielje JEA, Kruit WHJ, Schuler M et al. (1999) Phase I study of subcutaneously administered recombinatn human interleukin 12 in patients with advanced renal cell cancer. Clin Cancer Res 5: 3983–3989

    PubMed  CAS  Google Scholar 

  89. Pyrhönen S, Salminen E, Lehtonen T et al. (1996) Recombinant interferon alfa-2a with vinblastine vs. vinblastine alone in advanced renal cell carcinoma. A phase III study. Proc ASCO 1996: 244 (absr. 614)

    Google Scholar 

  90. Pyrhönen S, Slaminen E. Ruutu M et al. (1999) Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 17: 2859–2867

    PubMed  Google Scholar 

  91. Ravaud A, Audhuy B. Gomez F et al. (1998) Subcutaneous interleukin-2, interferon alfa-2a, and continuous infusion of fluorouracil in metastatic renal cell carcinoma: a multicenter phase II trial. J Clin Oncol 16: 2728–2723

    PubMed  CAS  Google Scholar 

  92. Renton KW, Deloria LB, Mennering GJ (1978) Efects of polyriboinosinic acid polyribocydidylic acid and a mouse interferon preparation on cytochrome P-450-dependent monooxygenase systems in cultures of primary mouse hepatocytes. Mol Pharmacol 14: 672–681

    PubMed  CAS  Google Scholar 

  93. Ritchie et members of MRC (1999) Interferon-a and survival in metastatic renal cell carcinoma: early results of a randomized controlled trial. Lancet 353: 14–17

    Article  Google Scholar 

  94. Rodriguez-Villanueva J, McDonnell TJ (1995) Induction of apoptotic cell death in non-melanoma skin cancer by interferon-alpha. Int J Cancer 61: 110–114

    Article  PubMed  CAS  Google Scholar 

  95. Rohde D (2000) Chemoimmuntherapie des metastasierten Nierenzellkarzinoms — Präklinische Grundlagen und klinische Anwendung einer neuartigen Kombinationstherapie aus 2′,2′,-Difluorodesoxycytidin und Interferonen. Habilitationsschrift, RWTH Aachen, 2000

    Google Scholar 

  96. Rohde D, De Mulder PHM, Weissbach L, Osieka R, Blatter J, Jakse G (1996) Experimental and clinical efficacy of 2′,2′-Difluorodeoxycytidin (Gemcitabin) against renal cell carcinoma. Oncology 53: 476–481

    Article  PubMed  CAS  Google Scholar 

  97. Rohde D, Goertz M, Hayn H, Cremer U, Jakse G (1997) Interferon-alpha and gemcitabine (2′,2′-difluorodeoxycytidin) in adult and pediatric renal tumors. Int J Oncol 11: 623–627

    PubMed  CAS  Google Scholar 

  98. Rohde D, Goertz M, Blatter J, Jakse G (1998) The efficacy of 2′,2′-difluorodeoxycytidin (gemcitabine) and vinblastine combined with interferon in nude mice xenografts of human renal cell carcinoma. Int J Oncol 12: 1367–1372

    PubMed  CAS  Google Scholar 

  99. Rohde D, Hayn HK, Blatter J, Jakse G (1998) The efficacy of 2′,2′-difluorodeoxycytidin (gemcitabine) combined with interferon in human renal cell carcinoma cell lines. Int J Oncol 12: 1361–1366

    PubMed  CAS  Google Scholar 

  100. Rohde D, Thiemann D, Wildberger J, Jakse G (1998) Preliminary data on treatment of renal cancer patients with gemcitabine (2′,2′-difluorodeoxycytidin) and interferons: anti-tumor activity and toxicity. Oncol Rep 5: 1555–1560

    PubMed  CAS  Google Scholar 

  101. Ryan CW, Vogelzang NJ, Dumas MC, Kuzel T, Stadler WM (2000) Granulocyte-macrophage-colony stimulating factor in combination immunotherapy for patients with metastatic renal cell carcinoma. Cancer 88(6): 1317–1324

    Article  PubMed  CAS  Google Scholar 

  102. Ryan CW, Vogelzang NJ, Dumas MC, Stadler WM (1999) A phase II trial of gemcitabine (GEM) and 5-FU with Il-2 and interferon alfa (IFNA) in patients (pts) with metastatic renal cell cancer. Proc ASCO 1999: abstr. 1264

    Google Scholar 

  103. Samland D, Steinbach F, Reiher F, Schmidt U, Gruss A, Allhoff E (1999) Results of immunochemotherapy with interleukin-2, interferon-alpha2 and 5-fluorouracil in the treatment of metastatic renal cell cancer . Eur Urol 35: 204–209

    Article  PubMed  CAS  Google Scholar 

  104. Schendel DJ, Falk CS, Nossner E, Maget B, Kressenstein S, Urlinger S, Tampe R(2000) Gansbacher B. Gene transfer of human interferon gamma complementary DNA into a renal cell carcinoma line enhances MHC-restricted cytotoxic T lymphocyte recognition but suppresses non-MHC-restricted effector cell activity. Gene Ther 7(11): 950–959

    Article  PubMed  CAS  Google Scholar 

  105. Schwaab T, Heaney JA, Schned AR et al. (2000) A randomized phase II trial comparing two different sequence combinations of autologous vaccine and human recombinant interferon ? and human recombinant interferon a2a therapy in patients with metastatic renal cell carcinoma: clinical outcome and analysis of immunological parameters. J Urol 163: 1322–1327

    Article  PubMed  CAS  Google Scholar 

  106. Selli C, Hinshaw WM, Woodard BH (1983) Stratification of risk factors in renal cell carcinoma. Cancer 52: 899–903

    Article  PubMed  CAS  Google Scholar 

  107. Silverberg E, Boring C, Squires T (1991) Cancer statistics. CA Cancer J Clin 41: 9–26

    Google Scholar 

  108. Simons JW, Jaffee EM, Weber et al. (1979) Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res 57(8): 1537–1546

    Google Scholar 

  109. The WHO Handbook for Reporting Results of cancer Treatment. World Health Organization, Geneva, Switzerland, p 48

    Google Scholar 

  110. Thompson JA, Figlin R, Galanis E, Bukowski R, Gillespie D, Selk L (2000) Phase II trial of plasmid DNA/Lipid (Leuvectin) immunotherapy in patients with metastatic renal cell carcinoma (RCC). Proc ASCO 2000: abstr. 1814

    Google Scholar 

  111. Tomita Y, Imai T, Katagiri A, Kimura M, Saitoh K, Sato S (1993) 5-Fluorouracil increases susceptibility of renal cell cancer cell lines to lymphokine-activated killer cells: evidence for alteration not at the level of recognition but at a post-binding stage of the lytic cycle. Cancer Lett 75: 27–34

    Google Scholar 

  112. Tourani JM, Pfister C, Berdah JF et al. (1998) Outpatient treatment with subcutaneous interleukin-2 and interferon alfa administration in combinations with fluorouracil in patients with metastaic renal cell carcinoma: results of a sequential nonrandomized phas II study. Subcutanous administration propeukin program cooperative Group. J Clin Oncol 16: 2505–2513

    PubMed  CAS  Google Scholar 

  113. Van Herpen CM, Jansen RL, Kruit WH, Hoekman K, Groenewegen G, Osanto S, de Mulder PH (2000) Immunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study. Dutch Immunotherapy working party. Br J Cancer 82(4): 772–776

    Article  PubMed  Google Scholar 

  114. Wadler S, Schwartz EL (1990) Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review. Cancer Res 50: 3473–3486

    PubMed  CAS  Google Scholar 

  115. Watanabe S, Arai Ki (1996) Roles of the JAK-STAT system in signal transduction via cytokine receptors. Curr Opin Genet Dev 6: 587–596

    Article  PubMed  CAS  Google Scholar 

  116. Wenzel C, Schmidinger MP, Locker GJ, Tomek S, Mader MR, Zielinski CC, Steger GG (2000) Oral chemotherapy with capecitabine (Xeloda) in the treatment of metastatic renal cancer failing immunotherapy . Proc. ASCO 2000: abstr. 1457

    Google Scholar 

  117. Yagoda A, Abi-Rached B, Petrylak D (1995) Chemotherapy for advanced renal-cell carcinoma. Semin Oncol 22: 42–60

    PubMed  CAS  Google Scholar 

  118. Yang JC, Popalian SL, Schwartzentruber DJ et al. (1995) The use of polyethylene glycolmodified interleukin-2 (PEG-IL-2) in the treatment of patients with metastatic renal cell carcinoma and melanoma. A phase I study and a randomized prospective study comparing IL-2 alone versus IL-2 combined with PEG-IL-2. Cancer 76: 687–694

    Article  PubMed  CAS  Google Scholar 

  119. Yang JC, Rosenberg SA (1997) An ongoing prospective randomized comparision of interleukin-2 regimens for the treatment of metastatic renal cell cancer. Cancer J Sci Am 3 (Suppl.): 79–84

    Google Scholar 

Download references

Authors
  1. D. Rohde
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Urologische Klinik und Poliklinik, Medizinische Hochschule Hannover, Carl-Neuberg-Str. 1, 30625, Hannover, Deutschland

    Michael C. Truss , Christian G. Stief , Stefan Machtens  & Udo Jonas (Direktor), ,  &  (Direktor)

  2. Zentrum Anästhesiologie, Medizinische Hochschule Hannover, Carl-Neuberg-Str. 1, 30625, Hannover, Deutschland

    Till Wagner

Rights and permissions

Reprints and permissions

Copyright information

© 2002 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Rohde, D. (2002). Chemo-Immuntherapie und Vakzinebehandlung des metastasierten Nierenzellkarzinoms. In: Truss, M.C., Stief, C.G., Machtens, S., Jonas, U., Wagner, T. (eds) Pharmakotherapie in der Urologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-09273-6_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-09273-6_3

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-41519-0

  • Online ISBN: 978-3-662-09273-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation